Xingbang Li1,#, Xuan Zheng2,#, Bowen Jin1, Yunyan Li1, Yongyu Shao1, Xiaoxian Deng1, Dingyang Li1, Shanshan Li1, Hongmei Zhou1, Jie Zhang3, Xianya Zhang4, Qunshan Shen1, Gangcheng Zhang2,*
Congenital Heart Disease, Vol.18, No.3, pp. 373-385, 2023, DOI:10.32604/chd.2023.028979
Abstract Background: Transcatheter closure of patent foramen ovale (PFO) has been widely accepted as a highly effective way to treat high-risk PFO-related diseases. However, traditional non-degradable occluders made of metal alloys will permanently exist in the body, resulting in thrombosis, valve damage, hemolysis, arrhythmia, or other complications. The biodegradable PFO occluder developed by Shanghai Mallow Medical Instrument Co., Ltd., China can be fully absorbed and degrade into nontoxic ingredients, reducing postoperative complications. Objectives: To study the safety and efficacy of biodegradable PFO occluders in treating PFO. Methods: This single-center clinical trial collected 30 patients treated with a biodegradable PFO occluder. The… More >
Graphic Abstract
Login
Register
